{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:29Z","timestamp":1786985429508,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA100632"],"award-info":[{"award-number":["CA100632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bneo.2025.100071","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:38:56Z","timestamp":1737635936000},"page":"100071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML"],"prefix":"10.1016","volume":"2","author":[{"given":"Patricia L.","family":"Kropf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3663-8554","authenticated-orcid":false,"given":"Woonbok","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raji","family":"Shameem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt","family":"Balch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-9336","authenticated-orcid":false,"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre J.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.bneo.2025.100071_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100071_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-015-0489-2","article-title":"Unraveling myelodysplastic syndromes: current knowledge and future directions","volume":"18","author":"Chamseddine","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"10.1016\/j.bneo.2025.100071_bib3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.6004\/jnccn.2013.0104","article-title":"Myelodysplastic syndromes: clinical practice guidelines in oncology","volume":"11","author":"Greenberg","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.bneo.2025.100071_bib4","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.24984","article-title":"Cause of death in patients with lower-risk myelodysplastic syndrome","volume":"116","author":"Dayyani","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bneo.2025.100071_bib5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100071_bib6","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100071_bib7","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bneo.2025.100071_bib8","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bneo.2025.100071_bib9","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100071_bib10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/asheducation-2013.1.511","article-title":"Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes","volume":"2013","author":"Saunthararajah","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.bneo.2025.100071_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bneo.2025.100071_bib12","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2025.100071_bib13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100071_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"Lubbert","year":"2012","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.bneo.2025.100071_bib15","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/bloodadvances.2017009829","article-title":"The role of targeted therapy in the management of patients with AML","volume":"1","author":"Perl","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2025.100071_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13148-015-0131-z","article-title":"Epigenetic synergy between decitabine and platinum derivatives","volume":"7","author":"Qin","year":"2015","journal-title":"Clin Epigenetics"},{"issue":"2","key":"10.1016\/j.bneo.2025.100071_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.leu.2401278","article-title":"Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia","volume":"13","author":"Larrea","year":"1999","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2025.100071_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.1991.9.1.39","article-title":"A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia","volume":"9","author":"Martinez","year":"1991","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100071_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JCO.1989.7.2.173","article-title":"Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses","volume":"7","author":"Meyers","year":"1989","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100071_bib20","first-page":"1072","article-title":"Phase II clinical trial of carboplatin in relapsed and refractory leukemia","volume":"6","author":"Vogler","year":"1992","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bneo.2025.100071_bib21","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/cncr.11314","article-title":"Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience","volume":"97","author":"Lazo","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bneo.2025.100071_bib22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/cncr.25686","article-title":"A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bneo.2025.100071_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/10428190903486212","article-title":"Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines","volume":"51","author":"Peng","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.bneo.2025.100071_bib24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ajh.22092","article-title":"Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study","volume":"86","author":"Welch","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100071_bib25","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-14-2391","article-title":"Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer","volume":"76","author":"Raynal","year":"2016","journal-title":"Cancer Res"},{"issue":"28","key":"10.1016\/j.bneo.2025.100071_bib26","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1200\/JCO.22.02768","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"41","author":"Calvert","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100071_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4161\/epi.4.3.8694","article-title":"LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors","volume":"4","author":"Aparicio","year":"2009","journal-title":"Epigenetics"},{"issue":"1","key":"10.1016\/j.bneo.2025.100071_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13148-019-0704-3","article-title":"Genomic and epigenomic predictors of response to guadecitabine in relapsed\/refractory acute myelogenous leukemia","volume":"11","author":"Chung","year":"2019","journal-title":"Clin Epigenetics"},{"issue":"24","key":"10.1016\/j.bneo.2025.100071_bib29","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100071_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2025.100071_bib31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00134-018-5426-z","article-title":"Adaptive designs in clinical trials in critically ill patients: principles, advantages and pitfalls","volume":"45","author":"van Werkhoven","year":"2019","journal-title":"Intensive Care Med"},{"issue":"32","key":"10.1016\/j.bneo.2025.100071_bib32","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","article-title":"Patient-reported outcomes and the evolution of adverse event reporting in oncology","volume":"25","author":"Trotti","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100071_bib33","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1038\/s41598-019-45982-7","article-title":"Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells","volume":"9","author":"Huynh","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.bneo.2025.100071_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115212","article-title":"Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond","volume":"406","author":"Maimaitiyiming","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100071_bib35","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bneo.2025.100071_bib36","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100071_bib37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.29085","article-title":"Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia","volume":"121","author":"Issa","year":"2015","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2025.100071_bib38","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2025.100071_bib39","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","article-title":"Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup study C9710","volume":"116","author":"Powell","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bneo.2025.100071_bib40","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2005.03.7903","article-title":"Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes","volume":"24","author":"Schiller","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100071_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1158\/1535-7163.MCT-16-0588","article-title":"Repositioning FDA-approved drugs in combination with epigenetic drugs to reprogram colon cancer epigenome","volume":"16","author":"Raynal","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.bneo.2025.100071_bib42","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.immuni.2021.06.006","article-title":"The neutrophil","volume":"54","author":"Burn","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.bneo.2025.100071_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.imlet.2020.07.007","article-title":"Plasticity of monocyte development and monocyte fates","volume":"227","author":"Trzebanski","year":"2020","journal-title":"Immunol Lett"},{"key":"10.1016\/j.bneo.2025.100071_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100791","article-title":"Current and emerging strategies for management of myelodysplastic syndromes","volume":"48","author":"Saygin","year":"2021","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.bneo.2025.100071_bib45","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.3390\/cancers12113225","article-title":"Advances in acute myeloid leukemia: recently approved therapies and drugs in development","volume":"12","author":"Stanchina","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.bneo.2025.100071_bib46","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.3390\/ijms23126568","article-title":"Arsenic trioxide and venetoclax synergize against AML progenitors by ROS induction and inhibition of Nrf2 activation","volume":"23","author":"Hoang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bneo.2025.100071_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100071_bib48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","article-title":"Clinical trial design in the era of precision medicine","volume":"14","author":"Fountzilas","year":"2022","journal-title":"Genome Med"},{"issue":"6","key":"10.1016\/j.bneo.2025.100071_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx013","article-title":"Adaptive clinical trials: advantages and disadvantages of various adaptive design elements","volume":"109","author":"Korn","year":"2017","journal-title":"J Natl Cancer Inst"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T02:54:03Z","timestamp":1756263243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2950328025000068"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100071","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100071"}}